Blood Res.  2013 Dec;48(4):274-281. 10.5045/br.2013.48.4.274.

Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

• Lee J
• Kim CY
• Park YJ
• Lee NK

• KMID: 2172875
• DOI: http://doi.org/10.5045/br.2013.48.4.274

Abstract

BACKGROUND
The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT).
METHODS
Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis.
RESULTS
The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56% vs. 41%, P=0.823) and 3-year overall survival (OS) (75% vs. 59%, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged < or =60 years had better OS rates.
CONCLUSION
The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age < or =60 years were associated with a better prognosis.

Keyword

Extranodal NK/T-cell lymphoma; Nasal type; Chemoradiotherapy; Treatment outcome

MeSH Terms

Chemoradiotherapy*
Disease-Free Survival
Drug Therapy*
Follow-Up Studies
Humans
Lymphoma*
Multivariate Analysis
Nasal Cavity
Prognosis
Radiotherapy*
Treatment Outcome